Compare · GLP-1 agonist
Liraglutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Semaglutide | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the better-studied metabolic drugs of the last fifteen years, and the direct predecessor to semaglutide. Its two approved uses rest on large, replicated, double-blind randomized trials with hard endpoints, so the honest job here is to separate what the evidence firmly supports…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.